Randox Release: Accurately And Efficiently Monitor The Performance Of HbA1c Assays
In order to have confidence in the patient results reported good quality control is essential. A good control should be consistent over repeated analysis; have a good working stability and a long shelf life Randox can provide just this.
The new HbA1c control from Randox is made from 100% human whole blood and is designed to accurately and efficiently monitor the performance of HbA1c assays.
Accurately assigned % HbA1c target values and ranges with corresponding Total Haemoglobin and HbA1c concentration values are provided for all major systems and methods including HPLC.
Our HbA1c controls are lyophilised providing enhanced shelf life and stability. An extended shelf life reduces the frequency of lot crossovers and allows you to sequester and use the same lot of control over a number of years significantly reducing reagent costs. A working stability of 28 days at 2-8oC minimises waste and saves money.
To complement our HbA1c controls an HbA1c linearity set is also available designed to verify the linearity of HbA1c assays across the clinically important range. Four clinically significant levels are provided eliminating the requirement for very low and or very high patient samples normally used to assess linearity. Like our HbA1c controls the linearity set is suitable for use on all platforms and contains accurately assigned values for the most common analysers and methods. In addition to this we also have an EQA programme available on RIQAS the world’s largest global EQA scheme.
For more information please visit www.randox.com or email marketing@randox.com
About Randox
Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.
For more information contact us at marketing@randox.com